

BIENAIME JEAN JACQUES

Form 4

January 02, 2018

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
BIENAIME JEAN JACQUES

2. Issuer Name and Ticker or Trading
Symbol

BIOMARIN PHARMACEUTICAL
INC [BMRN]

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction

(Month/Day/Year)

12/28/2017

☒ Director ☐ 10% Owner
☒ Officer (give title below) ☐ Other (specify below)

Chief Executive Officer

C/O BIOMARIN
PHARMACEUTICAL INC., 770
LINDARO ST.

(Street)

4. If Amendment, Date Original
Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check
Applicable Line)

☒ Form filed by One Reporting Person
☐ Form filed by More than One Reporting
Person

SAN RAFAEL, CA 94901

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | | | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|--------|------------|---------------------------|---|--|---|
| | | | Code | V | Amount | (A) or (D) | Price | | | |
| Common Stock | 09/26/2017 ⁽¹⁾ | 09/26/2017 | G | V | 430 | D | \$ 0 | 226,494 | D | |
| Common Stock | 12/14/2017 ⁽²⁾ | 12/14/2017 | G | V | 600 | D | \$ 0 | 225,894 | D | |
| Common Stock | 12/28/2017 ⁽³⁾ | 12/28/2017 | M | | 10,000 | A | \$ 38.59 | 235,894 | D | |
| Common Stock | 12/28/2017 ⁽³⁾ | 12/28/2017 | S | | 10,000 | D | \$ 89.8912 ⁽⁴⁾ | 225,894 | D | |

Edgar Filing: BIENAIME JEAN JACQUES - Form 4

| | | | | | | | | |
|--------------|---------------------------|------------|---|--------|---|----------|---------|---|
| Common Stock | 12/29/2017 ⁽³⁾ | 12/29/2017 | M | 10,000 | A | \$ 38.59 | 235,894 | D |
|--------------|---------------------------|------------|---|--------|---|----------|---------|---|

| | | | | | | | | |
|--------------|---------------------------|------------|---|--------|---|---------------------------------|---------|---|
| Common Stock | 12/29/2017 ⁽³⁾ | 12/29/2017 | S | 10,000 | D | \$ 89.6125 ⁽⁶⁾ | 225,894 | D |
|--------------|---------------------------|------------|---|--------|---|---------------------------------|---------|---|

| | | | | | | | | | |
|--------------|--|--|--|--|--|--|---------|---|---|
| Common Stock | | | | | | | 182,801 | I | Shares held by Jean-Jacques Bienaime Family Trust |
|--------------|--|--|--|--|--|--|---------|---|---|

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|
| | | | | Code | V (A) (D) | Date Exercisable Expiration Date | Title Amount or Number of Shares |
| Stock Option (Right to buy Common Stock) | \$ 38.59 | 12/28/2017 ⁽³⁾ | 12/28/2017 | M | 10,000 | 11/22/2008 05/21/2018 | Common Stock 10,000 |
| Stock Option (Right to buy Common Stock) | \$ 38.59 | 12/29/2017 ⁽³⁾ | 12/29/2017 | M | 10,000 | 11/22/2008 05/21/2018 | Common Stock 10,000 |

Reporting Owners

Reporting Owner Name / Address

Relationships

Reporting Owners

Edgar Filing: BIENAIME JEAN JACQUES - Form 4

Director 10% Owner Officer Other

BIENAIME JEAN JACQUES
C/O BIOMARIN PHARMACEUTICAL INC.
770 LINDARO ST.
SAN RAFAEL, CA 94901

X

Chief Executive Officer

Signatures

/s/ Laura Randall Woodhead,
Attorney-in-Fact

01/02/2018

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) On September 26, 2017, the reporting person gifted 430 shares to an educational institution.
- (2) On December 14, 2017, the reporting person gifted 600 shares to an educational institution.
- (3) Trade made pursuant to a 10b5-1 plan executed on November 14, 2017.

The price in column 4 is the weighted average price. The price actually received ranged from \$88.89 to \$90.92. The reporting person shall

- (4) provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.

- (5) Reflects the number of stock options outstanding after the transaction from this specific stock option grant.

The price in column 4 is the weighted average price. The price actually received ranged from \$88.97 to \$90.45. The reporting person shall

- (6) provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.